An interventional study of TESCoN or SCONE device - Thoracic stimulation and TESCoN or SCONE device - Lumbosacral stimulation in Spinal Cord Injury, Autonomic Dysfunction and Sexual Dysfunction, sponsored by University of British Columbia. Recruiting at 2 sites in Canada. Open to participants aged 19 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
This study is a pilot clinical trial to explore the efficacy of transcutaneous spinal cord stimulation (TCSCS) (proof-of-concept) in mitigating crucial autonomic dysfunctions that impact the health-related quality of life of individuals with spinal cord injury (SCI).
This is a pilot clinical trial to explore the efficacy of TCSCS (proof-of-concept) in mitigating crucial autonomic dysfunctions that impact the health-related quality of life of individuals with SCI. A total of 30 eligible participants will be recruited and attend forty-two visits. All experiments will be performed at ICORD (Primary site) and the Brenda and David McLean Integrated Spine Clinic (SCI clinic), with the exception of anorectal manometry testing conducted at the Gastroenterology Clinic, St Paul's Hospital (GI clinic).
Following completion of screening and signing informed consent forms (visit 1), participants will undergo spatiotemporal mapping of spinal cord segments known to be involved in blood pressure, lower urinary tract and bowel control (visit 2). Following mapping, all individuals will undergo baseline functional assessments with and without TCSCS during 5 visits (visits 3-7), over a period of 4 weeks. To minimize the order effect, the functional assessments will be performed in a randomized order. Following baseline assessments, using a randomized counter-balanced approach, individuals will be allocated in two distinct pathways; the participants in Groups 1 and 2 will receive 8 weeks of TCSCS (3 times/week) at either mid/low thoracic or lumbosacral spinal cord levels respectively (visits 8- 31). Following long-term TCSCS, participants will undergo functional assessments during 5 visits (visits 32- 36) over a period of 4 weeks. In order to evaluate the persistent effects of TCSCS, all assessments will be repeated 8 weeks after cessation of the therapy.
30 studies on the registry are indexed under Autonomic Dysreflexia; 10 are open to participants now.
This study's planned enrollment of 30 is above the median of 22 across 23 interventional studies indexed under Autonomic Dysreflexia.
Browse Autonomic Dysreflexia studies →University of British Columbia is the lead sponsor of 1,339 studies on the registry; 259 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Compared within Autonomic Dysreflexia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Spinal Cord Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For women of , not intending to become pregnant, currently pregnant, or lactating. The following conditions apply:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 8 weeks TCSCS at the mid/low thoracic spinal cord levels.
Device: TESCoN or SCONE device - Thoracic stimulation
Participants will receive 8 weeks TCSCS at the lumbosacral spinal cord levels.
Device: TESCoN or SCONE device - Lumbosacral stimulation
TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN or SCONE, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord.
TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN or SCONE, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord.
Targeted TCSCS map modulate resting blood pressure (BP)
Using continuous beat-by beat BP monitoring via finger photoplethysmography during TCSCS, the researchers will identify the location and stimulation parameters to increase and decrease resting BP. Stimulation site will be either on the thoracic spinal cord (T7-T12) or the lumbosacral spinal cord (L1 - L3). Stimulation will be applied at various frequencies ranging between 1Hz and 90Hz. The outcome is an individualized TCSCS map (i.e. location and stimulation parameters) with change in systolic BP at rest during TCSCS.
Time frame: Week 1-2 (once)
Targeted TCSCS map to activate skeletal muscles and pelvic floor muscles
Using surface electromyography (EMG), the researchers will identify the motor threshold for skeletal muscles known to be involved in lower urinary tract, bowel and sexual control by delivering TCSCS at various spinal cord segments (T7 to conus medullaris). The outcome is an individualized TCSCS map (i.e. location and stimulation parameters) with pertinent motor thresholds for TCSCS-driven surface EMG.
Time frame: Week 1-2 (once)
Immediate change in BP during the head up tilt test (HUTT)
During HUTT, participants will be passively moved to approximately 60° upright stand position by the investigators using the tilt table. Using TCSCS to activate spinal sympathetic circuitry and mitigate low resting BP and orthostatic hypotension (OH), and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of short-term TCSCS in reproducibly improving OH triggered by HUTT.
Time frame: Week 3 - 6 (once)
Change in BP during the head up tilt test (HUTT) from baseline to after completion of 8 weeks of TCSCS
Using TCSCS and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of long-term TCSCS in improving OH triggered by HUTT.
Time frame: Week 15-18 (once)
Change in BP during the head up tilt test (HUTT) from baseline to 8 weeks after cessation of TCSCS
Using TCSCS and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of long-term TCSCS in improving OH triggered by HUTT after cessation of therapy.
Time frame: Week 27-30 (once)
Immediate change in BP during digital anorectal stimulation (DARS)
DARS is a routine procedure to initiate a bowel routine. The participant will lay on their right side and DARS will be delivered via an index finger inserted into the rectum, applying gentle pressure for 30-60s. Utilizing TCSCS to inhibit nociceptive afferent and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of short-term TCSCS in reproducibly improving autonomic dysreflexia (AD) triggered by DARS.
Time frame: Week 3 - 6 (once)
Change in BP during digital anorectal stimulation (DARS) from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of long-term TCSCS in improving AD triggered by DARS.
Time frame: Week 15-18 (once)
Change in BP during digital anorectal stimulation (DARS) from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of TCSCS in improving AD triggered by DARS after cessation of therapy.
Time frame: Week 27-30 (once)
Immediate change in rectal pressure measured by anorectal manometry (ARM)
ARM is well-established methodology that provides a direct assessment of anal sphincter pressure and anorectal coordination during simulated defecation. The test is performed by inserting a catheter, that contains a probe embedded with pressure sensors, through the anus and into the rectum. Researchers will test the safety and efficacy of short-term TCSCS in reproducibly changing average max resting and squeeze pressure (mmHg).
Time frame: Week 3 - 6 (once)
Immediate change in high pressure anal canal zone measured by ARM
Researchers will test the safety and efficacy of short-term TCSCS in reproducibly changing length of high pressure anal canal zone (cm).
Time frame: Week 3 - 6 (once)
Immediate change in recto-anal inhibitory reflex measured by ARM
Researchers will test the safety and efficacy of short-term TCSCS in reproducibly changing recto-anal inhibitory reflex.
Time frame: Week 3 - 6 (once)
Immediate change in rectal sensation measured by ARM
Researchers will test the safety and efficacy of short-term TCSCS in reproducibly changing rectal sensation (mL).
Time frame: Week 3 - 6 (once)
Change in rectal pressure measured by ARM from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and ARM, researchers will test the safety and efficacy of long-term TCSCS in changing average max resting and squeeze pressure (mmHg).
Time frame: Week 15-18 (once)
Change in high pressure anal canal zone measured by ARM from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and ARM, researchers will test the safety and efficacy of long-term TCSCS in changing length of high pressure anal canal zone (cm).
Time frame: Week 15-18 (once)
Change in rectal sensation measured by ARM from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and ARM, researchers will test the safety and efficacy of long-term TCSCS in changing rectal sensation (mL).
Time frame: Week 15-18 (once)
Change in recto-anal inhibitory reflex measured by ARM from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and ARM, researchers will test the safety and efficacy of long-term TCSCS in changing recto-anal inhibitory reflex.
Time frame: Week 15-18 (once)
Change in rectal pressure measured by anorectal manometry (ARM) from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS and ARM, researchers will test the safety and efficacy of TCSCS in changing average max resting and squeeze pressure (mmHg).
Time frame: Week 27-30 (once)
Change in high pressure anal canal zone measured by anorectal manometry (ARM) from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS and ARM, researchers will test the safety and efficacy of TCSCS in changing length of high pressure anal canal zone (cm).
Time frame: Week 27-30 (once)
Change in recto-anal inhibitory reflex measured by anorectal manometry (ARM) from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS and ARM, researchers will test the safety and efficacy of TCSCS in changing recto-anal inhibitory reflex.
Time frame: Week 27-30 (once)
Change in rectal sensation measured by anorectal manometry (ARM) from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS and ARM, researchers will test the safety and efficacy of TCSCS in changing rectal sensation (mL).
Time frame: Week 27-30 (once)
Immediate change in intravesical pressure at first sensation measured by urodynamic investigation (UDI)
Standard clinical procedures for UDI, including cystometry with water at 21°C and a filling rate of \< 30 mL per minute through a 6F double lumen catheter with the participants in the supine position, provides a direct assessment of voiding and storage function. Abdominal pressure will be measured with a 10F intrarectal balloon catheter. Filling will be stopped when the participants report a sensation of fullness. Researchers will test the safety and efficacy of short-term TCSCS in reproducibly changing intravesical pressure at first sensation (mmHg).
Time frame: Week 3 - 6 (once)
Immediate change in intravesical pressure at leakage point measured by UDI
Filling will be stopped at the moment of urine leakage. Researchers will test the safety and efficacy of short-term TCSCS in reproducibly changing intravesical pressure at leakage point (mmHg).
Time frame: Week 3 - 6 (once)
Immediate change in intravesical pressure at maximal volume measured by UDI
Filling will be stopped at the moment of discomfort/per the request of patient. Researchers will test the safety and efficacy of short-term TCSCS in reproducibly changing intravesical pressure at maximal volume (mmHg).
Time frame: Week 3 - 6 (once)
Change in intravesical pressure at first sensation measured by UDI from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and UDI, researchers will test the safety and efficacy of long-term TCSCS in changing intravesical pressure at first sensation (mmHg).
Time frame: Week 15-18 (once)
Change in intravesical pressure at leakage point measured by UDI from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and UDI, researchers will test the safety and efficacy of long-term TCSCS in changing intravesical pressure at leakage point (mmHg).
Time frame: Week 15-18 (once)
Change in intravesical pressure at maximal volume measured by UDI from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and UDI, researchers will test the safety and efficacy of long-term TCSCS in changing intravesical pressure at maximal volume (mmHg).
Time frame: Week 15-18 (once)
Change in intravesical pressure at first sensation measured by UDI from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS and UDI, researchers will test the safety and efficacy of TCSCS in changing intravesical pressure at first sensation (mmHg).
Time frame: Week 27-30 (once)
Change in intravesical pressure at leakage point measured by UDI from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS and UDI, researchers will test the safety and efficacy of TCSCS in changing intravesical pressure at leakage point (mmHg).
Time frame: Week 27-30 (once)
Change in intravesical pressure at maximal volume measured by UDI from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS and UDI, researchers will test the safety and efficacy of TCSCS in changing intravesical pressure at maximal volume (mmHg).
Time frame: Week 27-30 (once)
Immediate change in BP during penile or clitoral vibrostimulation
Genital vibration will be applied by an experienced physician using one or more handheld vibrators placed about the glans penis or the clitoral area with an amplitude of 1.0-3.5 mm and a frequency of 70-100 Hz. Utilizing TCSCS to inhibit nociceptive afferent and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of short-term TCS in reproducibly improving AD triggered by vibrostimulation.
Time frame: Week 3 - 6 (once)
Change in BP during penile or clitoral vibrostimulation from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of long-term TCSCS in improving AD triggered by vibrostimulation.
Time frame: Week 15-18 (once)
Change in BP during penile or clitoral vibrostimulation from baseline to 8 weeks after cessation of TCSCS
Utilizing TCSCS to inhibit nociceptive afferent and continuous beat-by beat BP monitoring via finger photoplethysmography, researchers will test the safety and efficacy of TCSCS in improving AD triggered by vibrostimulation.
Time frame: Week 27-30 (once)
Baseline assessment of colonic motility using the wireless motility capsule
The wireless motility capsule will be ingested and pass naturally through the GI tract, and data will be sent wirelessly to the data receiver. Researchers will use the collected data to assess baseline transit times.
Time frame: Week 3 - 6 (once)
Change in colonic motility using the wireless motility capsule from baseline to after completion of 8 weeks of TCSCS
Utilizing TCSCS and the wireless motility capsule, researchers will test the safety and efficacy of long-term TCSCS in improving transit times.
Time frame: Week 15-18 (once)
Change in colonic motility using the wireless motility capsule from baseline to 8 weeks after TCSCS cessation.
Utilizing TCSCS and the wireless motility capsule, researchers will test the safety and efficacy of TCSCS in improving transit times after cessation of therapy.
Time frame: Week 27-30 (once)
Immediate change in cerebral blood flow (CBF) measured by trans-cranial doppler (TCD) during HUTT
TCD is a non-invasive ultrasound technique used to measure real-time CBF velocity. Researchers will test the safety and efficacy of short-term TCSCS in reproducibly improving CBF during HUTT.
Time frame: Week 3 - 6 (once)
Change in CBF measured by TCD during HUTT from baseline to after completion of 8 weeks of TCSCS
Researchers will test the safety and efficacy of long-term TCSCS in improving CBF during HUTT.
Time frame: Week 15-18 (once)
Change in CBF measured by TCD during HUTT from baseline to 8 weeks after TCSCS cessation
Researchers will test the safety and efficacy of TCSCS in improving CBF during HUTT after cessation of therapy.
Time frame: Week 27-30 (once)
Immediate change in performance on the verbal fluency test (VFT) during HUTT
Phonetic/letter fluency, specifically total number of words, will be measured using the verbal fluency test (VFT). Researchers will test the safety and efficacy of short-term TCSCS in reproducibly improving cognitive function during HUTT.
Time frame: Week 3 - 6 (once)
Change in performance on the VFT from baseline to after completion of 8 weeks of TCSCS
Researchers will test the safety and efficacy of long-term TCSCS in improving phonetic/letter fluency using the VFT.
Time frame: Week 15-18 (once)
Change in performance on the VFT from baseline to 8 weeks after TCSCS cessation
Researchers will test the safety and efficacy of TCSCS in improving phonetic/letter fluency after cessation of therapy.
Time frame: Week 27-30 (once)
Immediate change in performance on the Stroop Color and Word (SCW) test during HUTT
Ability to inhibit cognitive interference, specifically completion time, will be measured using the Stroop Color and Word (SCW) test. Researchers will test the safety and efficacy of short-term TCSCS in reproducibly improving completion time of the SCW.
Time frame: Week 3 - 6 (once)
Change in performance on SCW from baseline to after completion of 8 weeks of TCSCS
Researchers will test the safety and efficacy of short-term TCSCS in reproducibly improving completion time of the SCW.
Time frame: Week 15-18 (once)
Change in performance on SCW from baseline to 8 weeks after TCSCS cessation
Researchers will test the safety and efficacy of short-term TCSCS in reproducibly improving completion time of the SCW after cessation of therapy.
Time frame: Week 27-30 (once)
Frequency of urinary incontinence will be measured using The Incontinence-Quality of Life (I-QoL) questionnaire.
Assessment of urinary incontinence will be performed to assess the impact of long term TCSCS on this measure. The scale is a 100 point scale where 0 is most severe incontinence.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Neurogenic bladder symptoms will be measured using the Neurogenic Bladder Symptom Score (NBSS).
Assessment of neurogenic bladder symptoms will be performed to assess the impact of long term TCSCS on this measure. The score measures bladder symptoms across 3 different domains: incontinence (scored 0-29), storage and voiding (scored 0-22), and consequences (scored 0-23), with higher scores representing worse symptoms.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Frequency of fecal incontinence will be measured using the modified Wexner Fecal Incontinence Score (WIS).
Assessment of fecal incontinence will be performed to assess the impact of long term TCSCS on this measure. Scores can range from 0-20, with a higher score representing greater incontinence.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Neurogenic bowel symptoms will be measured using the Neurogenic Bowel Dysfunction (NBD) score.
Assessment of neurogenic bowel symptoms will be performed to assess the impact of long term TCSCS on this measure. Scores can range from 0-47, with a higher score representing more severe dysfunction.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Time Needed for Bowel Movement (TNFBM) will be measured by self-report.
Participants will be asked to record the time from 'suppository insertion' to 'when bowel evacuation is completed', during their regular bowel movement at home.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Participant's sexual function and satisfaction with their overall sexual life will be measured using the International Index of Erectile Function (IIEF-15).
This measure of sexual function will be used to assess whether sexual function is impacted by TCSCS. Scores can range from 5-25, with higher scores representing greater function.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Participant's sexual function and satisfaction with their overall sexual life will be measured using the Female Sexual Function Index (FSFI).
This measure of sexual function will be used to assess whether sexual function is impacted by TCSCS. Scores can range from 2-36, with higher scores representing greater function.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Participant's sexual function and satisfaction with their overall sexual life will be measured using a semi-structured qualitative interview.
This measure of sexual function will be used to assess whether sexual function is impacted by TCSCS.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Participant's sexually related personal distress will be measured using the Female Sexual Distress Scale (FSDS).
The FSDS is a 13-item self-report measure of sexually related personal distress in women. The 13 items of the scale are scored on a 5-point Likert scale ranging from 0 (never) to 4 (always). The total score is calculated as the sum of the responses and ranges from 0 to 52, with higher scores indicating a greater level of distress. A score of ≥11 serves as a cut-off value for diagnosing women with sexual distress.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Participant's sensations associated with orgasm will be measured using the Orgasm Rating Scale (ORS).
The ORS is a 28 item self-report measure of phenomenological sensations associated with orgasm in men and women. Items are scored from 0 (not at all) 5 (extremely), with total scores ranging from 0 to 140, and higher scores indicating better function.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Participant's quality of life will be measured using the Short Form Health Survey (SF-36)
The SF-36 consists of 8 domains pertaining to the respondents' experiences in the last 4 weeks. Each of the 8 summed scores is linearly transformed onto a scale from 0 (negative health) to 100 (positive health) to provide a score for each subscale.
Time frame: Week 3 - 6 (once), Week 15-18 (once), week 27-30 (once)
Plan to share: Yes — The research team plans to deposit final de-identified research data at a community-based repository for SCI research, such as Open Data Commons for SCI (https://odc-sci.org//). Research resources, including but not limited to, established stimulation parameter and recording equipment, will also be made available through material transfer agreement upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will be available upon full-text print publication in a peer-reviewed journal, for a duration of at least 10 years.
Access criteria: Online access or e-mail request to the corresponding author from an established scientific investigator
Started Oct 2023 (actual). Primary completion is estimated for Oct 2026, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →